Sihuan Pharmaceutical Holdings Group Ltd. (SHPHF)
OTCMKTS
· Delayed Price · Currency is USD
0.1000
-0.0218 (-17.90%)
May 7, 2025, 4:00 PM EDT
SHPHF Revenue
In the year 2024, Sihuan Pharmaceutical Holdings Group had annual revenue of 1.90B CNY with 2.18% growth. Sihuan Pharmaceutical Holdings Group had revenue of 951.41M in the half year ending December 31, 2024.
Revenue
1.90B CNY
Revenue Growth
+2.18%
P/S Ratio
3.22
Revenue / Employee
712.83K CNY
Employees
2,667
Market Cap
838.26M USD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.90B | 40.57M | 2.18% |
| Dec 31, 2023 | 1.86B | -320.65M | -14.70% |
| Dec 31, 2022 | 2.18B | -857.20M | -28.21% |
| Dec 31, 2021 | 3.04B | 574.17M | 23.30% |
| Dec 31, 2020 | 2.46B | -414.09M | -14.39% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo Inc. | 1.76B |
| Veradigm | 588.02M |
| Tian'an Technology Group | 1.78M |
| Glass House Brands | 200.90M |
| Elite Pharmaceuticals | 70.00M |
| Northwest Biotherapeutics | 1.38M |
| BioStem Technologies | 301.83M |
| American Oncology Network | 1.76B |
Sihuan Pharmaceutical Holdings Group News
- 2 years ago - Xuanzhu Biopharm, a subsidiary of Sihuan Pharmaceutical, Its Innovative Drug Anaprozole Sodium Enteric-coated Tablets Obtains Drug Registration Approval From NMPA - PRNewsWire